Literature DB >> 26216687

Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population.

Nan Lv1, Jian Qu2, Hongyu Long1, Luo Zhou1, Yuze Cao1, Lili Long1, Zhaoqian Liu2, Bo Xiao3.   

Abstract

PURPOSE: As important ion channels of the central nervous system, calcium channels not only take part in epileptogenesis but also act as the targets of commonly used antiepileptic drugs (AEDs). Thus, this study aimed to provide the first investigation of the association between CACNA1A, CACNA1C, and CACNA1H single nucleotide polymorphisms (SNPs) and AED resistance in the Chinese Han population.
METHODS: We performed genotyping of tagging single nucleotide polymorphisms (tagSNPs) of CACNA1A, 1C and 1H in 480 Chinese epilepsy patients (288 drug-responsive and 192 drug-resistant patients). The Illumina GoldenGate BeadArray assay was used to detect the genotypes of all of the patients. A total of 15 SNPs were selected based on the HapMap database. The genotype distributions in drug-responsive and drug-resistant patients were compared, and the haplotype frequencies of each gene were calculated.
RESULTS: None of the 15 tagSNPs alleles were found to be associated with drug-resistant epilepsy. However, the frequency of the TAGAA haplotype in CACNA1A was significantly higher in drug-resistant patients than in drug-responsive patients after the correction of multiple comparisons with Bonferroni's method (TAGAA 13.3% vs. 7.1%, OR=2.129 [1.373-3.299], P=0.00059<0.05/10).
CONCLUSIONS: This study revealed no association between the 15 tagSNPs of CACNA1A, 1C, and 1H and drug efficacy in the Chinese Han population. The TAGAA haplotype of CACNA1A may be a risk factor for AED resistance.
Copyright © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Association study; CACNA1A; CACNA1C; CACNA1H; Drug-resistant epilepsy; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26216687     DOI: 10.1016/j.seizure.2015.05.013

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  8 in total

Review 1.  Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

Authors:  Ramon Cacabelos
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

2.  Epilepsy and episodic ataxia type 2: family study and review of the literature.

Authors:  Lorenzo Verriello; Giada Pauletto; Annacarmen Nilo; Incoronata Lonigro; Elena Betto; Mariarosaria Valente; Francesco Curcio; Gian Luigi Gigli
Journal:  J Neurol       Date:  2021-05-13       Impact factor: 4.849

Review 3.  The pharmacogenomics of valproic acid.

Authors:  Miao-Miao Zhu; Hui-Lan Li; Li-Hong Shi; Xiao-Ping Chen; Jia Luo; Zan-Ling Zhang
Journal:  J Hum Genet       Date:  2017-09-07       Impact factor: 3.172

4.  Epilepsy and Hearing Loss in a Patient with a Rare Heterozygous Variant in the CACNA1H Gene.

Authors:  Hussein A Algahtani; Bader H Shirah; Ahmed Samman; Abdulellah Alhazmi
Journal:  J Epilepsy Res       Date:  2022-06-30

5.  Genetic Association of Epilepsy and Anti-Epileptic Drugs Treatment in Jordanian Patients.

Authors:  Laith N Al-Eitan; Islam M Al-Dalala; Afrah K Elshammari; Wael H Khreisat; Aseel F Nimiri; Adan H Alnaamneh; Hanan A Aljamal; Mansour A Alghamdi
Journal:  Pharmgenomics Pers Med       Date:  2020-10-16

6.  Next-generation sequencing improves treatment efficacy and reduces hospitalization in children with drug-resistant epilepsy.

Authors:  Jing Peng; Nan Pang; Ying Wang; Xiao-Le Wang; Jian Chen; Juan Xiong; Pan Peng; Can-Hui Zhu; Miriam Barakael Kessi; Fang He; Fei Yin
Journal:  CNS Neurosci Ther       Date:  2018-06-22       Impact factor: 5.243

7.  Blood DNA methylation pattern is altered in mesial temporal lobe epilepsy.

Authors:  Hong-Yu Long; Li Feng; Jin Kang; Zhao-Hui Luo; Wen-Biao Xiao; Li-Li Long; Xiao-Xin Yan; Luo Zhou; Bo Xiao
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

Review 8.  Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.

Authors:  Alfredo B Cuéllar-Barboza; Susan L McElroy; Marin Veldic; Balwinder Singh; Simon Kung; Francisco Romo-Nava; Nicolas A Nunez; Alejandra Cabello-Arreola; Brandon J Coombes; Miguel Prieto; Hannah K Betcher; Katherine M Moore; Stacey J Winham; Joanna M Biernacka; Mark A Frye
Journal:  Int J Bipolar Disord       Date:  2020-07-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.